Physician profile
David Andrew Mclain
NPI 1689614737
$587,904.82
in general payments reported to CMS, 2019-2025
60 companies · $222K in 2025
The $222K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,210 · 2020: $3,724 · 2021: $5,795 · 2022: $84K · 2023: $79K · 2024: $187K · 2025: $222K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $472K · Food and Beverage: $15K · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $472,302.50 |
| Food and Beverage | $15,418.62 |
| Education | $268.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557,055.50 | 2019-2025 | |
| Amgen INC. | $4,487.97 | 2019-2025 | Enbrel, Otezla, Evenity |
| Ucb, INC. | $3,024.85 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $2,899.69 | 2019-2025 | Benlysta |
| Pfizer INC. | $2,627.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,328.66 | 2019-2025 | |
| Janssen Biotech, INC. | $1,733.69 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Mallinckrodt Hospital Products INC. | $1,706.92 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $1,361.05 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $1,122.76 | 2019-2025 | Orencia |
| Lilly USA, LLC | $828.70 | 2019-2025 | Taltz, Zepbound |
| Genzyme Corporation | $819.83 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $683.72 | 2019-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $663.65 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $640.86 | 2019-2023 | Krystexxa |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.